GlobeNewswire: Accelerate Diagnostics, Inc. Contains the last 10 of 55 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T09:08:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/07/19/1539800/0/en/Accelerate-Diagnostics-to-Review-Second-Quarter-2018-Results-on-August-6th.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics to Review Second Quarter 2018 Results on August 6th2018-07-19T18:30:00Z<![CDATA[TUCSON, Ariz., July 19, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will host a conference call on Monday, August 6, 2018 to review the company’s second quarter 2018 financial results and commercial progress.]]>https://www.globenewswire.com/news-release/2018/06/05/1517189/0/en/Accelerate-Diagnostics-to-Present-at-the-William-Blair-38th-Annual-Growth-Stock-Conference.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics to Present at the William Blair 38th Annual Growth Stock Conference2018-06-05T15:30:00Z<![CDATA[TUCSON, Ariz., June 05, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, President and Chief Executive Officer is scheduled to speak at the William Blair 38th Annual Growth Stock Conference in Chicago, Illinois on Wednesday, June 13, 2018 at 2:40 PM, Central Time.]]>https://www.globenewswire.com/news-release/2018/05/09/1499833/0/en/Accelerate-Diagnostics-reports-Q1-2018-financial-results.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics reports Q1 2018 financial results2018-05-09T20:03:00Z<![CDATA[TUCSON, Ariz., May 09, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018. The company generated revenue of $801,000, up 51% from the prior year, and reported signed agreements for 345 instruments. Contracts for customer evaluations total 256 instruments while revenue generating placements grew to 89 across the U.S. and European regions.]]>https://www.globenewswire.com/news-release/2018/04/30/1490087/0/en/Accelerate-Diagnostics-to-Review-First-Quarter-2018-Results-on-May-9th.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics to Review First Quarter 2018 Results on May 9th2018-04-30T14:42:30Z<![CDATA[TUCSON, Ariz., April 30, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will host a conference call on Wednesday, May 9, 2018 to review its first quarter 2018 financial results and commercial progress.]]>https://www.globenewswire.com/news-release/2018/04/21/1483635/0/en/Accelerate-Diagnostics-announces-sizeable-release-of-new-data-at-ECCMID-2018.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics announces sizeable release of new data at ECCMID 20182018-04-21T07:37:55Z<![CDATA[Four integrated symposium sessions, 11 poster presentations, and case studies will cover the clinical value of integrating diagnostic stewardship into current sepsis protocols given the rising rates of antibiotic resistance Four integrated symposium sessions, 11 poster presentations, and case studies will cover the clinical value of integrating diagnostic stewardship into current sepsis protocols given the rising rates of antibiotic resistance]]>https://www.globenewswire.com/news-release/2018/03/23/1449173/0/en/Accelerate-Diagnostics-Inc-Announces-Pricing-of-150-Million-Convertible-Notes-Offering.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering2018-03-23T06:15:00Z<![CDATA[TUCSON, Ariz., March 23, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (“Accelerate Diagnostics”) (NASDAQ:AXDX) today announced the pricing of $150.0 million aggregate principal amount of 2.50% convertible senior notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). An entity affiliated with one of Accelerate Diagnostics’s directors has agreed to purchase an aggregate of $30 million of the notes. Accelerate Diagnostics also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the notes.]]>https://www.globenewswire.com/news-release/2018/03/22/1444191/0/en/Accelerate-Diagnostics-Inc-Announces-150-Million-Convertible-Notes-Offering.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics Inc. Announces $150 Million Convertible Notes Offering2018-03-22T11:08:27Z<![CDATA[TUCSON, Ariz., March 22, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced its intention to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of convertible senior notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). Accelerate Diagnostics also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the notes.]]>https://www.globenewswire.com/news-release/2018/02/15/1349156/0/en/Accelerate-Diagnostics-reports-Q4-and-Full-Year-Financial-Results-for-2017.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 20172018-02-15T21:05:00Z<![CDATA[TUCSON, Ariz., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced preliminary full-year 2017 financial results including the quarter ending December 31, 2017. The company reported revenue for Q4 of $2.1 million, doubling revenue for the year, and signed agreements for 337 instruments. Contracts for customer evaluations covered 259 instruments while revenue placements totaled 78 across the U.S., European, and Middle East regions.]]>https://www.globenewswire.com/news-release/2018/02/08/1336671/0/en/Accelerate-Diagnostics-to-Host-Q4-and-Full-Year-2017-Earnings-Call-on-February-15-2018.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 20182018-02-08T22:25:09Z<![CDATA[TUCSON, Ariz., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. will host a conference call on Thursday, February 15, 2018 to review its fourth quarter and full-year financial results for 2017.]]>https://www.globenewswire.com/news-release/2018/01/10/1286596/0/en/Accelerate-Diagnostics-achieves-CE-IVD-milestone-for-severe-bacterial-pneumonia-assay-doubles-revenue-for-2017-in-Q4.html?f=22&fvtc=4&fvtv=23527Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q42018-01-10T12:57:00Z<![CDATA[TUCSON, Ariz., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79/EC and CE mark of its latest assay for the Accelerate Pheno™ system targeting severe bacterial pneumonia infections. During the related study, results for the severe pneumonia assay were available about 57 hours faster than the standard of care.]]>